Navigation Links
Deltanoid Pharmaceuticals begins phase II osteoporosis study

Madison, Wis. - Deltanoid Pharmaceuticals, a privately held pharmaceutical company based in Madison, has begun a Phase 2 clinical study of 2MD, its lead osteoporosis compound.

The study is being conducted to determine whether 2MD can safely improve bone mineral density in postmenopausal women. Osteoporosis, a disease caused by the loss of norm......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 03/13/07


Page: 1

Related biology technology :

1. Deltanoid presses on with drug research
2. Deltanoid named to top-15 list of biotech companies
3. The Coming of Biotech Generic Pharmaceuticals
4. DeForest biodiesel plant begins production
5. Prodesse begins clinical trials for flu virus detection
6. Closing the income gap begins with education
7. Corporate control begins with a strong board
8. Emerging game developer begins work on prototypes
9. GE begins human trials for cancer detection agent
10. Now the real work begins
11. Esker begins automated faxing and mailing service
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... N.C. (PRWEB) , ... October 09, 2017 , ... At ... announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, ... Stubbs was a member of the winning team for the 2015 Breakthrough Prize in ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):